Sadhana Nitro Chem Ltd
Incorporated in 1973, Sadhana Nitro Chem Ltd manufactures chemical intermediates, heavy organic chemicals performance chemicals, and wireless network equipment and services[1]
- Market Cap ₹ 827 Cr.
- Current Price ₹ 2.79
- High / Low ₹ 3.16 / 1.27
- Stock P/E
- Book Value ₹ 1.54
- Dividend Yield 3.58 %
- ROCE -11.2 %
- ROE -23.6 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -14.8% over past five years.
- Company has a low return on equity of -8.69% over last 3 years.
- Company has high debtors of 1,275 days.
- Company's cost of borrowing seems high
- Promoter holding has decreased over last 3 years: -10.8%
- Working capital days have increased from 442 days to 939 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Commodity Chemicals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 48 | 35 | 57 | 110 | 267 | 120 | 90 | 121 | 146 | 189 | 133 | 41 | |
| 51 | 33 | 49 | 76 | 147 | 83 | 72 | 107 | 123 | 145 | 94 | 94 | |
| Operating Profit | -3 | 2 | 9 | 35 | 120 | 37 | 18 | 14 | 23 | 44 | 39 | -54 |
| OPM % | -7% | 6% | 15% | 32% | 45% | 31% | 20% | 11% | 16% | 23% | 30% | -133% |
| 13 | 0 | 0 | 0 | 1 | 2 | 4 | 5 | 2 | 4 | 3 | 8 | |
| Interest | 5 | 5 | 6 | 5 | 12 | 3 | 3 | 5 | 10 | 17 | 18 | 26 |
| Depreciation | 2 | 2 | 2 | 2 | 3 | 5 | 6 | 6 | 8 | 15 | 15 | 16 |
| Profit before tax | 3 | -5 | 1 | 28 | 106 | 31 | 13 | 8 | 7 | 16 | 9 | -88 |
| Tax % | -33% | -0% | -0% | -11% | 29% | 25% | 21% | 32% | 35% | 54% | 43% | -1% |
| 4 | -5 | 1 | 31 | 75 | 24 | 10 | 6 | 5 | 7 | 5 | -87 | |
| EPS in Rs | 0.01 | -0.02 | 0.00 | 0.11 | 0.26 | 0.08 | 0.04 | 0.02 | 0.02 | 0.02 | 0.02 | -0.29 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | 51% | 66% | 50% | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | -15% |
| 3 Years: | -35% |
| TTM: | -70% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -1773% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | -17% |
| 3 Years: | -47% |
| 1 Year: | 53% |
| Return on Equity | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | -5% |
| 3 Years: | -9% |
| Last Year: | -24% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 9 | 9 | 9 | 9 | 14 | 20 | 20 | 25 | 33 | 296 |
| Reserves | -7 | -12 | 2 | 37 | 95 | 114 | 119 | 145 | 208 | 208 | 251 | 160 |
| 37 | 42 | 36 | 16 | 8 | 46 | 83 | 116 | 139 | 233 | 247 | 113 | |
| 26 | 28 | 37 | 55 | 66 | 49 | 90 | 99 | 61 | 71 | 107 | 91 | |
| Total Liabilities | 66 | 68 | 83 | 116 | 179 | 218 | 306 | 380 | 428 | 536 | 639 | 661 |
| 31 | 29 | 37 | 39 | 67 | 76 | 70 | 67 | 144 | 156 | 149 | 163 | |
| CWIP | 9 | 9 | 9 | 11 | 2 | 15 | 23 | 68 | 28 | 53 | 100 | 78 |
| Investments | 0 | 0 | 0 | 0 | 5 | 6 | 6 | 7 | 6 | 6 | 2 | 0 |
| 26 | 30 | 37 | 66 | 105 | 122 | 207 | 238 | 250 | 321 | 387 | 420 | |
| Total Assets | 66 | 68 | 83 | 116 | 179 | 218 | 306 | 380 | 428 | 536 | 639 | 661 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 | -1 | 10 | 44 | 52 | -11 | 1 | -4 | -38 | -2 | 48 | -31 | |
| -0 | -0 | -1 | -14 | -25 | -28 | -23 | -40 | -53 | -65 | -99 | -46 | |
| -6 | 2 | -6 | -14 | -23 | 30 | 30 | 46 | 72 | 41 | 34 | 93 | |
| Net Cash Flow | 0 | 0 | 4 | 16 | 4 | -8 | 7 | 2 | -19 | -26 | -16 | 16 |
| Free Cash Flow | 6 | -1 | 9 | 38 | 32 | -33 | -23 | -45 | -86 | -68 | -45 | -95 |
| CFO/OP | -182% | -49% | 115% | 132% | 51% | 19% | 8% | 32% | -145% | -3% | 131% | 53% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 58 | 135 | 83 | 25 | 46 | 156 | 236 | 121 | 200 | 282 | 363 | 1,275 |
| Inventory Days | 99 | 177 | 174 | 192 | 197 | 374 | 641 | 695 | ||||
| Days Payable | 220 | 401 | 321 | 122 | 141 | 197 | 273 | 357 | ||||
| Cash Conversion Cycle | -63 | -89 | -64 | 95 | 103 | 333 | 604 | 121 | 200 | 282 | 363 | 1,613 |
| Working Capital Days | -212 | -326 | -120 | -73 | 35 | 86 | 121 | 85 | 210 | 191 | 195 | 939 |
| ROCE % | -13% | 1% | 17% | 62% | 135% | 24% | 8% | 5% | 5% | 8% | 5% | -11% |
Insights
In beta| Sep 2018 | Mar 2020 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Total permanent employees employees |
|
||||
| ODB2 (SND 27) Colour Former Installed Capacity TPA |
|||||
| Number of countries exported to countries |
|||||
| PAP (Para Amino Phenol) Installed Capacity TPA |
|||||
| Aniline 2,5 Di Sulphonic Acid (ANDS) Installed Capacity TPA |
|||||
| Export Volume tonnes |
|||||
| Nitrobenzene (NB) Installed Capacity TPA |
|||||
| MAP (Meta Amino Phenol) Installed Capacity TPA |
|||||
| R&D Expenditure (Percentage of Turnover) % |
|||||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Intimation for Consideration And Approval Of Unaudited Standalone And Consolidated Financial Results Along With The Limited Review Report Of The Company For The Quarter Ended June 30, 2026.
31 Jul - Board meets on 7 August 2026 to approve Q1 FY27 results.
-
Receipt Of In-Principle Approval From BSE Limited ('BSE') And National Stock Exchange Of India Limited ('NSE') For Proposed Preferential Issue Of 6,75,00,000 Equity Shares Of Re. 1/- Each Of The Company.
28 Jul - BSE and NSE granted in-principle approval for 6.75 crore preferential equity shares.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026; 2 demat requests confirmed within timelines.
- Closure of Trading Window 25 Jun
-
Announcement Under Regulation 30 (LODR) - Issue And Allotment Of 6,75,00,000 Equity Shares Having Face Value Of Re. 1 Each On A Preferential Basis
1 Jun - 6.75 crore preferential shares allotted at ₹2.06, floor price ₹2.05.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
SNCL is an ISO 9001:2015 certified and a government-recognized 2-Star Golden Export House. It is in the business of chemical and chemical products, pharma, medicinal chemicals, and intermediates